Compile Data Set for Download or QSAR
Report error Found 23 Enz. Inhib. hit(s) with all data for entry = 9804
TargetVascular endothelial growth factor receptor 2(Human)
Kala Pharmaceuticals

US Patent
LigandPNGBDBM412189(US10398703, Compound 9 | US10966987, Compound 9)
Affinity DataKd:  490nMAssay Description:A VEGFR2 tagged T7 phage strain was prepared in an Escherichia coli (E. coli) derived from the BL21 strain. The E. coli were grown to log-phase, infe...More data for this Ligand-Target Pair
Ligand InfoSimilars
In Depth
Date in BDB:
10/9/2021
Entry Details
US Patent

TargetVascular endothelial growth factor receptor 2(Human)
Kala Pharmaceuticals

US Patent
LigandPNGBDBM412193(US10398703, Compound 16 | US10966987, Compound 16)
Affinity DataKd:  520nMAssay Description:A VEGFR2 tagged T7 phage strain was prepared in an Escherichia coli (E. coli) derived from the BL21 strain. The E. coli were grown to log-phase, infe...More data for this Ligand-Target Pair
Ligand InfoSimilars
In Depth
Date in BDB:
10/9/2021
Entry Details
US Patent

TargetVascular endothelial growth factor receptor 2(Human)
Kala Pharmaceuticals

US Patent
LigandPNGBDBM412197(US10398703, Compound 30 | US10966987, Compound 30)
Affinity DataKd:  690nMAssay Description:A VEGFR2 tagged T7 phage strain was prepared in an Escherichia coli (E. coli) derived from the BL21 strain. The E. coli were grown to log-phase, infe...More data for this Ligand-Target Pair
Ligand InfoSimilars
In Depth
Date in BDB:
10/9/2021
Entry Details
US Patent

TargetVascular endothelial growth factor receptor 2(Human)
Kala Pharmaceuticals

US Patent
LigandPNGBDBM412203(US10398703, Compound 49 | US10966987, Compound 49)
Affinity DataKd:  980nMAssay Description:A VEGFR2 tagged T7 phage strain was prepared in an Escherichia coli (E. coli) derived from the BL21 strain. The E. coli were grown to log-phase, infe...More data for this Ligand-Target Pair
Ligand InfoSimilars
In Depth
Date in BDB:
10/9/2021
Entry Details
US Patent

TargetVascular endothelial growth factor receptor 2(Human)
Kala Pharmaceuticals

US Patent
LigandPNGBDBM412194(US10398703, Compound 17 | US10966987, Compound 17)
Affinity DataKd:  1.00E+3nMAssay Description:A VEGFR2 tagged T7 phage strain was prepared in an Escherichia coli (E. coli) derived from the BL21 strain. The E. coli were grown to log-phase, infe...More data for this Ligand-Target Pair
Ligand InfoSimilars
In Depth
Date in BDB:
10/9/2021
Entry Details
US Patent

TargetVascular endothelial growth factor receptor 2(Human)
Kala Pharmaceuticals

US Patent
LigandPNGBDBM412210(US10398703, Compound 57 | US10966987, Compound 57)
Affinity DataKd:  1.30E+3nMAssay Description:A VEGFR2 tagged T7 phage strain was prepared in an Escherichia coli (E. coli) derived from the BL21 strain. The E. coli were grown to log-phase, infe...More data for this Ligand-Target Pair
Ligand InfoSimilars
In Depth
Date in BDB:
10/9/2021
Entry Details
US Patent

TargetVascular endothelial growth factor receptor 2(Human)
Kala Pharmaceuticals

US Patent
LigandPNGBDBM412198(US10398703, Compound 35 | US10966987, Compound 35)
Affinity DataKd:  1.30E+3nMAssay Description:A VEGFR2 tagged T7 phage strain was prepared in an Escherichia coli (E. coli) derived from the BL21 strain. The E. coli were grown to log-phase, infe...More data for this Ligand-Target Pair
Ligand InfoSimilars
In Depth
Date in BDB:
10/9/2021
Entry Details
US Patent

TargetVascular endothelial growth factor receptor 2(Human)
Kala Pharmaceuticals

US Patent
LigandPNGBDBM412208(US10398703, Compound 55 | US10966987, Compound 55)
Affinity DataKd:  1.70E+3nMAssay Description:A VEGFR2 tagged T7 phage strain was prepared in an Escherichia coli (E. coli) derived from the BL21 strain. The E. coli were grown to log-phase, infe...More data for this Ligand-Target Pair
Ligand InfoSimilars
In Depth
Date in BDB:
10/9/2021
Entry Details
US Patent

TargetVascular endothelial growth factor receptor 2(Human)
Kala Pharmaceuticals

US Patent
LigandPNGBDBM412209(US10398703, Compound 56 | US10966987, Compound 56)
Affinity DataKd:  2.40E+3nMAssay Description:A VEGFR2 tagged T7 phage strain was prepared in an Escherichia coli (E. coli) derived from the BL21 strain. The E. coli were grown to log-phase, infe...More data for this Ligand-Target Pair
Ligand InfoSimilars
In Depth
Date in BDB:
10/9/2021
Entry Details
US Patent

TargetVascular endothelial growth factor receptor 2(Human)
Kala Pharmaceuticals

US Patent
LigandPNGBDBM412190(US10398703, Compound 12 | US10966987, Compound 12)
Affinity DataKd:  3.20E+3nMAssay Description:A VEGFR2 tagged T7 phage strain was prepared in an Escherichia coli (E. coli) derived from the BL21 strain. The E. coli were grown to log-phase, infe...More data for this Ligand-Target Pair
Ligand InfoSimilars
In Depth
Date in BDB:
10/9/2021
Entry Details
US Patent

TargetVascular endothelial growth factor receptor 2(Human)
Kala Pharmaceuticals

US Patent
LigandPNGBDBM412206(US10398703, Compound 53 | US10966987, Compound 53)
Affinity DataKd:  3.30E+3nMAssay Description:A VEGFR2 tagged T7 phage strain was prepared in an Escherichia coli (E. coli) derived from the BL21 strain. The E. coli were grown to log-phase, infe...More data for this Ligand-Target Pair
Ligand InfoSimilars
In Depth
Date in BDB:
10/9/2021
Entry Details
US Patent

TargetVascular endothelial growth factor receptor 2(Human)
Kala Pharmaceuticals

US Patent
LigandPNGBDBM412196(US10398703, Compound 25 | US10966987, Compound 25)
Affinity DataKd:  4.80E+3nMAssay Description:A VEGFR2 tagged T7 phage strain was prepared in an Escherichia coli (E. coli) derived from the BL21 strain. The E. coli were grown to log-phase, infe...More data for this Ligand-Target Pair
Ligand InfoSimilars
In Depth
Date in BDB:
10/9/2021
Entry Details
US Patent

TargetVascular endothelial growth factor receptor 2(Human)
Kala Pharmaceuticals

US Patent
LigandPNGBDBM412201(US10398703, Compound 43b | US10966987, Compound 43...)
Affinity DataKd:  8.70E+3nMAssay Description:A VEGFR2 tagged T7 phage strain was prepared in an Escherichia coli (E. coli) derived from the BL21 strain. The E. coli were grown to log-phase, infe...More data for this Ligand-Target Pair
Ligand InfoSimilars
In Depth
Date in BDB:
10/9/2021
Entry Details
US Patent

TargetVascular endothelial growth factor receptor 2(Human)
Kala Pharmaceuticals

US Patent
LigandPNGBDBM412211(US10398703, Compound 58 | US10966987, Compound 58)
Affinity DataKd:  1.00E+4nMAssay Description:A VEGFR2 tagged T7 phage strain was prepared in an Escherichia coli (E. coli) derived from the BL21 strain. The E. coli were grown to log-phase, infe...More data for this Ligand-Target Pair
Ligand InfoSimilars
In Depth
Date in BDB:
10/9/2021
Entry Details
US Patent

TargetVascular endothelial growth factor receptor 2(Human)
Kala Pharmaceuticals

US Patent
LigandPNGBDBM412199(US10398703, Compound 38 | US10966987, Compound 38)
Affinity DataKd:  1.00E+4nMAssay Description:A VEGFR2 tagged T7 phage strain was prepared in an Escherichia coli (E. coli) derived from the BL21 strain. The E. coli were grown to log-phase, infe...More data for this Ligand-Target Pair
Ligand InfoSimilars
In Depth
Date in BDB:
10/9/2021
Entry Details
US Patent

TargetVascular endothelial growth factor receptor 2(Human)
Kala Pharmaceuticals

US Patent
LigandPNGBDBM412202(US10398703, Compound 48 | US10966987, Compound 48)
Affinity DataKd:  1.40E+4nMAssay Description:A VEGFR2 tagged T7 phage strain was prepared in an Escherichia coli (E. coli) derived from the BL21 strain. The E. coli were grown to log-phase, infe...More data for this Ligand-Target Pair
Ligand InfoSimilars
In Depth
Date in BDB:
10/9/2021
Entry Details
US Patent

TargetVascular endothelial growth factor receptor 2(Human)
Kala Pharmaceuticals

US Patent
LigandPNGBDBM412192(US10398703, Compound 15 | US10966987, Compound 15)
Affinity DataKd:  2.00E+4nMAssay Description:A VEGFR2 tagged T7 phage strain was prepared in an Escherichia coli (E. coli) derived from the BL21 strain. The E. coli were grown to log-phase, infe...More data for this Ligand-Target Pair
Ligand InfoSimilars
In Depth
Date in BDB:
10/9/2021
Entry Details
US Patent

TargetVascular endothelial growth factor receptor 2(Human)
Kala Pharmaceuticals

US Patent
LigandPNGBDBM412204(US10398703, Compound 50 | US10966987, Compound 50)
Affinity DataKd:  2.50E+4nMAssay Description:A VEGFR2 tagged T7 phage strain was prepared in an Escherichia coli (E. coli) derived from the BL21 strain. The E. coli were grown to log-phase, infe...More data for this Ligand-Target Pair
Ligand InfoSimilars
In Depth
Date in BDB:
10/9/2021
Entry Details
US Patent

TargetVascular endothelial growth factor receptor 2(Human)
Kala Pharmaceuticals

US Patent
LigandPNGBDBM412207(US10398703, Compound 54 | US10966987, Compound 54)
Affinity DataKd:  2.70E+4nMAssay Description:A VEGFR2 tagged T7 phage strain was prepared in an Escherichia coli (E. coli) derived from the BL21 strain. The E. coli were grown to log-phase, infe...More data for this Ligand-Target Pair
Ligand InfoSimilars
In Depth
Date in BDB:
10/9/2021
Entry Details
US Patent

TargetVascular endothelial growth factor receptor 2(Human)
Kala Pharmaceuticals

US Patent
LigandPNGBDBM412200(US10398703, Compound 43a | US10966987, Compound 43...)
Affinity DataKd:  3.10E+4nMAssay Description:A VEGFR2 tagged T7 phage strain was prepared in an Escherichia coli (E. coli) derived from the BL21 strain. The E. coli were grown to log-phase, infe...More data for this Ligand-Target Pair
Ligand InfoSimilars
In Depth
Date in BDB:
10/9/2021
Entry Details
US Patent

TargetVascular endothelial growth factor receptor 2(Human)
Kala Pharmaceuticals

US Patent
LigandPNGBDBM412191(US10398703, Compound 14 | US10966987, Compound 14)
Affinity DataKd:  3.70E+4nMAssay Description:A VEGFR2 tagged T7 phage strain was prepared in an Escherichia coli (E. coli) derived from the BL21 strain. The E. coli were grown to log-phase, infe...More data for this Ligand-Target Pair
Ligand InfoSimilars
In Depth
Date in BDB:
10/9/2021
Entry Details
US Patent

TargetVascular endothelial growth factor receptor 2(Human)
Kala Pharmaceuticals

US Patent
LigandPNGBDBM412195(US10398703, Compound 21 | US10966987, Compound 21)
Affinity DataKd:  5.80E+4nMAssay Description:A VEGFR2 tagged T7 phage strain was prepared in an Escherichia coli (E. coli) derived from the BL21 strain. The E. coli were grown to log-phase, infe...More data for this Ligand-Target Pair
Ligand InfoSimilars
In Depth
Date in BDB:
10/9/2021
Entry Details
US Patent

TargetVascular endothelial growth factor receptor 2(Human)
Kala Pharmaceuticals

US Patent
LigandPNGBDBM412205(US10398703, Compound 52 | US10966987, Compound 52)
Affinity DataKd:  1.20E+5nMAssay Description:A VEGFR2 tagged T7 phage strain was prepared in an Escherichia coli (E. coli) derived from the BL21 strain. The E. coli were grown to log-phase, infe...More data for this Ligand-Target Pair
Ligand InfoSimilars
In Depth
Date in BDB:
10/9/2021
Entry Details
US Patent